At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs ...

The Tylenol poisonings allowed him an opportunity to prove his loyalty to the medical drug behemoth. Hayes “lost little time in publicly exonerating Johnson & Johnson,” writes Harris.

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

Johnson & Johnson, while primarily known as America's leading healthcare company, now employs nearly 7,000 digital specialists and data scientists.

investors cite weak medical device sales Depression drug Spravato expected to generate $3 billion-3.5 billion in annual sales by 2028 April 15 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab ...